Events in our system are self-managed.  Group and event managers are encouraged to review privacy and security settings, and adjust them if needed.  If you need assistance please contact Indico Support - contact Help at bottom of page.

Apr 1 – 5, 2019
Fairmont Château Laurier Hotel
UTC timezone

Biparatopic targeting of epidermal growth factor receptor positive breast cancer cells using domain I/II and domain III specific antibody conjugates

Not scheduled
Fairmont Château Laurier Hotel

Fairmont Château Laurier Hotel




Biparatopic targeting of epidermal growth factor receptor positive breast cancer cells using domain I/II and domain III specific antibody conjugates Ayaz Ahmed KB1, Causey P2, Solomon VR1, Bernhard W3, Barreto K3, Wilson JJ4, Geyer CR3,Fonge H1,5. 1Department of Medical Imaging, University of Saskatchewan 2Canadian Nuclear Lab. Chalk River, ON 3Department of Pathology and Laboratory Medicine, University of Saskatchewan 4Department of Chemistry & Chemical Biology, Cornell University 5Department of Medical Imaging, Royal University Hospital Saskatoon Background: Epidermal growth factor receptor (EGFR) is overexpressed in > 50% of breast cancer. EGFR consists of an extracellular or ligand binding domain which consists of four binding epitopes (domains I, II, III, IV). Anti-EGFR therapeutic antibodies such as nimotuzumab and cetuximab bind to domain III of EGFR. For the first time we have developed an antibody that binds to epitope I & II of EGFR called FabH. Our hypothesis is that simultaneous targeting of domains I/II and III using immunoconjugates that are specific to these epitopes can lead to enhanced therapeutic outcome in EGFR positive cancers. To accomplish this we aimed to deliver potent alpha particle to domain I/II using 225Ac-FABH (radioimmunotherapy) and potent cytotoxic agent (PEGylated maytansine using nimotuzumab-PEG6-DM1 antibody drug conjugate (an ADC) to domain III. Methods: FABH was conjugated to an eight-membered macrocyclic chelator SCN-macropa, and then radiolabeled with 225Ac. The radiochemical yield of 225Ac-FABH was >90%. We investigated the cytotoxicity of this biparatopic approach in EGFR-positive breast cancer cells. 225Ac-FABH and nimotuzumab-PEG6-DM1 were developed and characterized by flow cytometry, bioanalyzer, HPLC and internalization rate (live-cell imaging). In vitro cytotoxicity was studied in MDA-MB-468, MDA-MB-231 and TrR1 EGFR-positive triple negative breast cancer cells. In vitro cytotoxicity using the biparatopic approach (225Ac-FABH + nimotuzumab-PEG6-DM1) was compared with 225Ac-FABH, + nimotuzumab-PEG6-DM1 or control non-specific immunoconjugates. Results: Bioanalyzer showed the purity and size of FabH, nimotuzumab, nimotuzumab-PEG6-DM1, and their respective macropa conjugated immunoconjugates. Flow cytometry showed nearly > 90% binding to the cells. In all three cell lines, in vitro studies showed enhanced cytotoxicity of 225Ac-FABH + nimotuzumab-PEG6-DM1 compared with the single agents FABH, nimotuzumab, nimotuzumab-PEG6-DM1, 225Ac-FABH or non-specific (radio)immunoconjugates which was evident from low IC50 values ranging from 12nM<<<47nM<<65nM<<105nM<<125nM respectively. Conclusions: The delivery of multiple cytotoxic agents to EGFR using this biparatopic approach is very promising in vitro. In vivo studies using mouse xenografts are planned.
Email Address
Presentation Type Poster

Primary author


Presentation materials

There are no materials yet.